Related Experiment Video
Updated: Jun 3, 2026
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
Hybridoma technologies for antibody production
Masahiro Tomita1, Kanta Tsumoto
1Division of Chemistry for Materials, Graduate School of Engineering, Mie University, Tsu, Mie 514-8507, Japan. tomita@chem.mie-u.ac.jp
Immunotherapy
|March 15, 2011
Summary
This study introduces a novel hybridoma technology for enhanced monoclonal antibody production. It enables selective B cell-myeloma fusion, improving efficiency and specificity for clinical applications.
Area of Science:
- Immunology
- Biotechnology
- Cell Biology
Background:
- Hybridoma technology is crucial for monoclonal antibody production.
- Standard methods lack selectivity in fusing B lymphocytes with myeloma cells.
- Targeted antibody generation requires overcoming fusion inefficiencies.
Purpose of the Study:
- To develop an advanced hybridoma technology for selective B cell-myeloma fusion.
- To enable efficient production of specific monoclonal antibodies.
- To facilitate the generation of human monoclonal antibodies for clinical use.
Main Methods:
- Preselection of B lymphocytes based on immunoglobulin receptors and target antigens.
- Selective fusion of B cell-myeloma cell complexes using electrical pulses.
- Development of B-cell targeting, multitargeting, and stereospecific targeting methodologies.
Main Results:
- Achieved selective fusion of target B lymphocytes with myeloma cells.
- Demonstrated applicability to simultaneous monoclonal antibody production.
- Showcased potential for producing stereospecific and human monoclonal antibodies.
Conclusions:
- The novel hybridoma technology significantly improves the selectivity and efficiency of monoclonal antibody generation.
- This advanced methodology offers versatile applications in antibody production for research and clinical purposes.
- The technique holds promise for developing targeted immunotherapies and diagnostics.
